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Background: Inhibition of the proteolytic activity of 26S proteasome, the protein-degrading machine, is now
considered a novel and promising approach for cancer therapy. Interestingly, proteasome inhibitors have been
demonstrated to selectively kill cancer cells and also enhance the sensitivity of tumor cells to chemotherapeutic
agents. Recently, polyphenols/flavonoids have been reported to inhibit proteasome activity. Murraya koenigii
Spreng, a medicinally important herb of Indian origin, has been used for centuries in the Ayurvedic system of
medicine. Here we show that Murraya koenigii leaves (curry leaves), a rich source of polyphenols, inhibit the
proteolytic activity of the cancer cell proteasome, and cause cell death.
Methods: Hydro-methanolic extract of curry leaves (CLE) was prepared and its total phenolic content [TPC]
determined by, the Folin-Ciocalteau’s method. Two human breast carcinoma cell lines: MCF-7 and MDA-MB-231
and a normal human lung fibroblast cell line, WI-38 were used for the studies. Cytotoxicity of the CLE was assessed
by the MTT assay. We studied the effect of CLE on growth kinetics using colony formation assay. Growth arrest was
assessed by cell cycle analysis and apoptosis by Annexin-V binding using flow cytometry. Inhibition of the
endogenous 26S proteasome was studied in intact cells and cell extracts using substrates specific to 20S
proteasomal enzymes.
Results: CLE decreased cell viability and altered the growth kinetics in both the breast cancer cell lines in a
dose-dependent manner. It showed a significant arrest of cells in the S phase albeit in cancer cells only. Annexin V
binding data suggests that cell death was via the apoptotic pathway in both the cancer cell lines. CLE treatment
significantly decreased the activity of the 26S proteasome in the cancer but not normal cells.
Conclusions: Our study suggests M. koenigii leaves to be a potent source of proteasome inhibitors that lead to
cancer cell death. Therefore, identification of active component(s) from the leaf extract could lead to the
development of anti-cancer agents which could be useful in the treatment of different types of cancers.
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Breast cancer is the second most prevalent cancer in the
world next only to lung cancer [1] and is a major public
health problem in developing countries like India. Every
year 75,000 new cases of breast cancer are reported in
India. The increase in the number of cases has been
attributed to factors such as genetics, environmental pol-
lution, urbanization and changing food habits.
Murraya koenigii Spreng (curry-leaf tree), is a small aro-
matic tree belonging to the family Rutaceae. It is a tropical
to sub-tropical tree native to India. Of the 14 global
species belonging to the genus Murraya, only two are
available in India, namely, M. koenigii and M. paniculata.
Of the two M. koenigii is more popular due to its large
spectrum of medicinal properties. M. koenigii leaves have
a slightly pungent, bitter and feebly acidulous taste and
these characteristics are retained even after drying. Fresh
and dried curry leaves are extensively used in South Indian
culinary practices for seasoning and flavouring dishes [2].
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Figure 1 Curry leaf extract decreases cell viability of breast cancer ce
treatment with CLE, whereas Panel C shows results of MTT assay after 24 h
MDA-MB-231 cell line. Panels D & E shows results of MTT assay after 12 h
assay after 24 h treatment with MG-132, in MCF-7 cell line. The data reprefruit are known to possess various biological activities.
Traditionally, this plant is used in Indian systems of medi-
cine for a variety of ailments and also used as a tonic,
stomachic, and carminative [3-5].
The major chemical constituents of the plant reported
are carbazole alkaloids, coumarins and flavonoids [6]. M.
koenigii leaf extracts exhibit hypoglycemic and hypolipi-
demic effects in experimental animals [7-9]. Carbazole
alkaloids and methanolic extracts of M. koenigii are also
reported to possess anti-oxidative [10-12], anti-diarrheal
and anti-trichomonal activities [13,14]. M. koenigii leaf
extracts reduced blood cholesterol and glucose levels in
ob/ob mice [15]. Methanolic extract of M. koenigii leaves
possess anti-inflammatory [16] and immunomodulatory
activity [17]. Mahanine, a carbazole alkaloid purified
from M. koenigii leaves has apoptotic effects in human
leukemia cells [18-20].
We and others have shown that a hydro-methanolic
extract of M. koenigii leaves is rich in phenolic content



















































Conc of CLE (µg of GAE)
lls: Panels A & B shows results of MTT assay after 12 h and 24 h
treatment with MG-132, a specific proteasome inhibitor respectively in
and 24 h treatment with CLE, whereas Panel F shows results of MTT
sents mean+/− SEM of three independent experiments.
AB
Vehicle g                   
Vehicle g                   
Figure 2 Curry leaf extract alters growth kinetics of breast cancer cells: Panel A depicts results of colony formation assay in MDA-MB-231
cell line. Panel B depicts results of colony formation assay in MCF-7 cell line. Cells were grown in 6-well plates and treated with various
concentrations of the CLE (0- 50 μg GAE). After a week cells were stained with crystal violet and photographed.
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metal-chelating properties [22,23]. Recent studies have
shown that naturally occurring polyphenols/flavanoids
modulate the functionality of the 26S proteasome, a multi-
enzymatic, multi-catalytic complex localized both in the
cytoplasm and nucleus of eukaryotic cells [24,25]. The 26S
proteasome is a huge 2.4 MDa complex comprising of two
sub-complexes – the 19S regulatory subunit and the 20S
catalytic subunit [26]. The 20S sub-unit possesses at least
three distinct activities, which are associated with the three
different β subunits respectively: chymotrypsin-like activity
(β5), trypsin-like activity (β2) and the caspase-like activity
(β1) [27]. The 26S proteasome is the major non-lysosomal
pathway of protein degradation in eukaryotic cells. This
proteolytic machine is involved in the degradation of oxi-
dized, unfolded and misfolded proteins and antigen presen-
tation [28-31]. It regulates several cellular processes such as
apoptosis, signal transduction, cell-cycle regulation and cell
differentiation [32]. Two important functions of the prote-
asome system are to promote tumor cell proliferation and
protect tumor cells against apoptosis [27,33,34].
In the present work, we demonstrate for the first time
that the hydro-methanolic extract of M. koenigii leaves rich
in phenolic content, potently inhibits the activity of the pro-
teasome both in vitro and in vivo. The CLE induced cell
death in two breast cancer cell lines in a time and dose-
dependent manner. The leaf extract altered the growth
kinetics of the cancer cells in a dose-dependent manner as
demonstrated by the colony formation assay. Cancer cells
but not normal cells were arrested in the S phase of the cell




Dulbecco’s Modified Eagle’s Medium (DMEM)- cell culture
media, antibiotic-antimycotic mix, sodium pyruvate, non-
essential amino acid mix and stable glutamine were
purchased from Himedia (Mumbai, India); fetal bovine
serum (FBS) was purchased from (GIBCO, Invitro-
gen USA), 3-[4, 5-dimethyltiazol-2-yl]-2.5-diphenyl-tetra-
zolium bromide (MTT), Dimethylsulfoxide (DMSO),
Propidium Iodide, Ribonuclease A, Dithiothreitol (DTT),
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesul-
fonate (CHAPS), Ethylene diamine tetra acetic acid
(EDTA), Phenyl methyl sulfoxide (PMSF), Crystal-violet,
Sodium dodecyl sulphate (SDS) and 4-(2-Hydroxyethyl)
piperazine-1-ethanesulfonic acid N-(2-Hydroxyethyl)pi-
perazine-N′-(2-ethanesulfonic acid) (HEPES) were pur-
chased from Sigma-Aldrich (St Louis, MO, USA). The
fluorogenic proteasomal peptide substrates Suc-LLVY-
AMC (chymotrypsin-like substrate), BOC-Leu-Arg-Arg-
AMC (trypsin -like substrate) and Z-Leu-Leu-Glu-AMC
(caspase- like substrate) and MG-132 (carbobenzoxy-Leu-
Leu-leucinal - a specific inhibitor of the 26S proteasome)
were procured from ENZO Life sciences, USA. 20S rabbit
proteasome was purchased from Boston Biochem, USA. All
other reagents were procured from Qualigens fine chemi-
cals (Mumbai, India). Annexin staining was done using a kit
(Annexin V-FITC Apoptosis detection kit; BD Pharmingen,
San Jose, CA, USA).
Vehicle 3µg CLE
6µg CLE 12.5µg CLE
25µg CLE
Figure 3 Cell cycle arrest by CLE in the MDA-MB-231 breast carcinoma cell line. Cell cycle analysis of MDA-MB-231 cells treated with
varying concentrations of CLE for 24 h was done by flow cytometry.
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Vehicle                                                                          12.5ug CLE
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Figure 4 Cell cycle arrest by CLE in the MCF-7 breast carcinoma cell line. Cell cycle analysis of MCF-7 cells treated with varying
concentrations of CLE for 24 h was done by flow cytometry.
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Table 1 Distribution [%] of MDA-MB-231 cells in different
phases of the cell cycle
CELL PHASE VEHICLE 3 μg 6 μg 12.5 μg 25 μg
G0-G1 43.98 54.15 44.53 33.9 37.3
S 52.07 37.26 53 66.10 62.6
G2-M 3.95 8.59 2.48 0.0 0.0
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Curry leaves were collected from the local area from a
single tree. Identity of the curry leaves was confirmed by
Dr. B. Pratibha Devi, Professor and Head, Department of
Botany, Osmania University, Hyderabad, India. A vou-
cher specimen (voucher no: 068) was deposited in a
herbarium at the Department of Botany, Osmania Uni-
versity, Hyderabad, India. The leaves were washed and
air dried in shade for 3 weeks. After drying, the leaves
were ground to a fine powder using an electric mixer
grinder. The leaf powder was extracted with 80% metha-
nol in water by keeping on a vortex mixer for 3-4days.
This was followed by centrifugation of the extract at
5000 rpm for 30 min. The supernatant was filtered using
a 0.4 μm filter (Millipore). The resultant Methanol:
Water extract was stored at −20°C and was used for all
our studies. These extracts designated as ‘CLE’, were
used in the cell-culture assays at different doses based
on their total phenolic content [equivalent to μg of gallic
acid (GAE)] measured spectrophotometrically by the
Folin-Ciocalteau method.
Total Phenolic Content (TPC)
The total phenolic content of the extract was deter-
mined with Folin–Ciocalteau’s reagent using Gallic acid
as a standard [35]. Different concentrations of Gallic
acid standards (20-100 μg/μl) and CLE samples were
taken in glass test tubes and volume was made up to
150 μl with distilled water. 750 μl of 10% Folin’s reagent
was added and kept for 5 minutes at room temperature,
followed by addition of 750 μl of 6% Na2CO3 and vor-
texed for 5 minutes. The tubes were then incubated for
90 minutes at room temperature. The absorbance was
measured at 725 nm in a Hitachi double beam spectro-
photometer. The final concentration of the total poly-
phenols present in the extract was expressed as μg of
Gallic Acid Equivalents (GAEs).Table 2 Distribution [%] of MCF-7 cells in different
phases of the cell cycle
CELL PHASE VEHICLE 12.5 μg 25 μg 37.5 μg 50 μg
G0-G1 63.51 52.24 56.42 35.62 44.46
S 27.89 38.22 34.68 64.38 55.54
G2-M 8.60 9.59 8.89 0.0 0.0Cell lines
MCF-7 and MDA-MB-231 (breast carcinoma cell lines)
and WI-38 (normal human lung fibroblasts) were
obtained from the National Centre for Cell Sciences, Pune,
India. Cells were maintained in DMEM supplemented
with 10% FBS, 2 mM Higluta-XL, 100 units/ml penicillin,
100 μg/ml streptomycin and 0.5 ng/ml amphotericin B,
1 mM sodium pyruvate and 1X non-essential amino acid
mixture. Cells were maintained and grown in a humidified
atmosphere at 37°C and 5% CO2. WI-38 cells were grown
for no more than 30 passages, as recommended by
European Collection of Cell Cultures (ECACC).
Cell viability/proliferation assay
Cell viability was determined by quantification of 3-(4,5-
dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium bromide
(MTT) reduction by mitochondrial dehydrogenases. In
brief, 1 × 105 cells/well were plated in a 96-well plate
and incubated with different concentrations of the CLE
for either 12 h or 24 h or with MG-132 for 24 h. Follo-
wing this, MTT was added to a final concentration of
100 μg/well and further incubated for 3 h at 37°C. The
formazan dye crystals formed were solubilized in DMSO
and the plate was incubated at room temperature for
1 h. The absorbance was measured at 595 nm in an
ELISA microplate reader (Biotek, New York, USA). All
samples were assayed in triplicate in three independent
experiments. Absorbance values plotted are the mean
from three independent experiments and the results are
expressed as percentage of the control, which was con-
sidered to be 100%.
Colony formation assay
MCF-7 and MDA-MB-231 cells were plated in duplicate
at a density of 1 × 104 and 1 × 103 cells/ml respectively
in 6-well plates. Next day, the cells were treated with
varying concentrations of CLE. Plates were incubated
at 37°C and 5% CO2 for one week. After a week, the
colonies were fixed with 4% formaldehyde for 15mins
followed by staining with 0.005% crystal violet. The
colonies were photographed with a digital Nikon D90
camera. Three independent experiments were done with
each cell line.
Cell cycle analysis and annexin V binding assay
Cell cycle analysis: MCF-7 or MDA-MB-231 or WI-38
cells were plated at a density of 1.5 × 106 cells in a 10 cm
dish. Next day, cells were treated with different doses of
the CLE. After 24 h incubation, cells were harvested and
suspended in 1X-PBS containing 2% FBS. The cells were
fixed with 70% ethanol at 4°C for 1 h followed by the
addition of propidium iodide (5 μg/ μl) and RNase (10 μg/
μl) and further incubated for 3 h at 4°C. The DNA content
was evaluated in a flow cytometer (BD FACS ARIAII,
Vehicle 12.5µg CLE
25µg CLE 50µg CLE
Figure 5 CLE treatment does not arrest cell cycle in the WI-38 normal lung fibroblast cell line. Cell cycle analysis of WI-38 cells treated
with varying concentrations of CLE for 24 h was done by flow cytometry.
Noolu et al. BMC Complementary and Alternative Medicine 2013, 13:7 Page 8 of 17
http://www.biomedcentral.com/1472-6882/13/7
Table 3 Distribution [%] of WI-38 cells in different phases
of the cell cycle
CELL PHASE VEHICLE 12.5 μg 25 μg 50 μg
G0-G1 48.7 55.83 48.57 52.8
S 50.35 44.16 51.43 47.20
G2-M 0.87 0.00 0.00 0.00
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Biosciences, USA).
Annexin-V staining: MCF-7 or MDA-MB-231 cells were
plated at a density of 1.5 × 106 cells in a 10 cm dish. Next
day, cells were treated with different doses of the CLE.
After 24 h incubation, cells were washed with 1X-PBS and
re-suspended in 100μl binding buffer (supplied by the
vendor). Cells were stained with Annexin V-FITC and
propidium iodide according to the manufacturer’s proto-
col before analysis by flow cytometry.
Inhibition of purified 20S proteasome activity
Chymotrypsin-like activity of the purified 20S proteasome
was measured as follows: In brief, 200 ng of purified 20S
proteasome was incubated in 200μl of assay buffer
(50 mmol/LTris–HCl, pH 8.0 containing 0.035% SDS) with
or without different concentrations of CLE and 40 μM
substrate Suc-Leu-Leu-Val-Tyr-AMC (for chymotrypsin-
like activity) and incubated for 2h at 37°C. The free 7-
amino-4-methylcoumarin (AMC) liberated was measured
fluorimetrically using a multi-mode reader [Spectra Max
M5] using an excitation filter (380 nm) and emission filter
(460 nm). The data is plotted as mean (+/− standard error)
and is expressed as a percentage of the control, which was
considered to be 100%. The assay was repeated thrice.
Inhibition of 26S proteasome activity in intact cells
To measure inhibition of the proteasome activity in
living tumor cells, MCF-7 or MDA-MB-231 or WI-38
cells were plated at a density of 1 × 104 in a 24 well
plate. Next day, cells were treated with or without the
CLE at the indicated concentrations. After 24 h of treat-
ment, the media was aspirated out and 500 μl of 1X-PBS
was added followed by addition of fluorogenic substrates
(20 μM final concentration) specific for the chymotrypsin-
like (Ch-L), trypsin-like (T-L) and caspase-like (Cp-L)
activities of the 20S proteasome. The plate was then incu-
bated for 2 h at 37°C. 200 μl of the 1X- PBS was then
transferred into a black plate and the free 7-amino-
4-methylcoumarin (AMC) liberated was measured fluori-
metrically in a multi-mode reader [Spectra Max M5] at
excitation (380 nm) and emission (460 nm). The results are
displayed as mean (+/− standard error) and are expressed
as a percentage of the control, which was considered to be
100%. All samples were assayed in triplicate in three inde-
pendent experiments.Inhibition of 26S proteasome activity in cell extracts
MCF-7 or MDA-MB-231 cells (1 × 107) were harvested,
washed twice in 1X-PBS and re-suspended in 1 ml ATP/
DTT lysis buffer [10 mmol/L Tris–HCl (pH 7.8), 5 mmol/
L ATP, 0.5 mmol/l DTT, 5 mmol/L MgCl2]. Cells were
incubated on ice for 10 minutes, followed by sonication
for 15 seconds. The lysate was centrifuged at 2000 rpm for
10 minutes at 4°C. The supernatant enriched in 26S pro-
teasomes is the cell extract which was used for the assay.
This was mixed with glycerol (20% final concentration),
aliquoted and stored at −80°C, and was stable for at least 1
month. The total protein content of the cell extract was
estimated by the Bicinchoninic Acid (BCA) method using
a kit (Bangalore Genei, Bangalore, India). The assay was
carried out in a total of 200 μl reaction volume containing
proteasome extract (50 μg protein), 50 mM EDTA, vary-
ing concentrations of the CLE/MG-132 and 50 μM of the
proteasomal fluorogenic substrates and incubated for 2 h
at 37°C. The amount of free 7-amino-4-methylcoumarin
(AMC) liberated was measured fluorimetrically. The
results are expressed as mean (+/− standard error) as a
percentage of the control, which was considered to be
100%. All samples were assayed in triplicate in three in-
dependent experiments.
Statistical analysis
All experiments were performed in triplicates and repeated
at least three times and the data are presented as mean+/−
SEM. Mean values were compared across concentrations of
CLE using non-parametric test of Kruskal-Wallis one-way
ANOVA for each cell line using the SPSS statistical soft-
ware. Differences between groups were considered signifi-
cant at α (probability) level of </= 0.05.
Results
M. koenigii leaf extract alters viability and growth kinetics
of breast cancer cells
The TPC of the methanolic extract of curry leaves was 3 μg
of GAEs/μl of the CLE. MTT assays were performed with
different concentrations of CLE (GAE) in both the cell lines
at the 12 h and 24 h time points to assess the effect of the
extract on cell viability. There was a significant (p<0.05)
time and dose-dependent decrease in cell viability in both
the cell lines. As expected, the decrease in cell viability
observed after 24 h of treatment was higher compared to
12 h. In addition, MDA-MB-231 cells (Figure 1A and 1B)
appeared to be more sensitive to CLE induced cell death
than MCF-7 cells (Figure 1D and 1E). 24 h post treatment,
a 50% reduction in cell viability was observed in MDA-MB-
231 and MCF-7 cells at 15 μg and 37.5 μg GAE of CLE
respectively. As a positive control, the effect of MG-132- a
specific inhibitor of the proteolytic activity of the 26S prote-
asome was also assessed on cell viability in both the breast
cancer cell lines. 24 h post treatment with MG-132, a 50%
Vehicle 6µg CLE
12.5µg CLE 18µg CLE
25µg CLE 37.5µg CLE
Figure 6 Exposure to CLE induces apoptosis in the MDA-MB-231 breast carcinoma cell line. Phosphatidylserine levels were detected by
annexin V-FITC binding. MDA-MB-231 cells were treated with varying concentrations of the CLE for 24 h and stained with FITC-conjugated
annexin V and propidium iodide (PI).
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Vehicle                                               12.5µg CLE
25µg CLE 50µg CLE
Necrotic cells(Q1)
Live cells (Q3)
Early Apoptotic Cells (Q4)
Late Apoptotic Cells (Q2)
Figure 7 Exposure to CLE induces apoptosis in the MCF-7 breast carcinoma cell line. Phosphatidylserine levels were detected by annexin
V-FITC binding. MCF-7 cells were treated with varying concentrations of the CLE for 24 h and stained with FITC-conjugated annexin V and
propidium iodide (PI).
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A
Figure 9 Inhibition of the enzymatic activities of the 26S
proteasome by the CLE in intact MDA-MB-231 breast cancer
cell line. Intact MDA-MB-231 were treated for 24 h with or without
the CLE followed by 2 h incubation at 37°C with the fluorogenic
substrate for Ch-L or T-L or Cp-L activities respectively. The
fluorescent intensity of the free AMCs was determined in a
multimode reader with excitation (380 nm) and emission (460 nm).
Each activity was expressed as the percentage of the control


















Conc of CLE (µg of GAE)
Figure 8 Curry leaf extract inhibits activity of purified 20S
proteasome. Purified 20S proteasome from rabbit was incubated
with 40 μM of fluorogenic peptide substrate for Ch-L activity in the
presence of various concentrations of the CLE for 2 h at 37°C. The
fluorescence intensity of the free AMCs was determined using
fluorescence mode in a multimode reader with excitation (380 nm)
and emission (460 nm).
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>40 μM of MG-132 in MDA-MB-231and MCF-7 cells re-
spectively (Figure 1C and 1F).
To test the effect of CLE on growth kinetics, MCF-7 and
MDA-MB-231 cells were seeded at a lower density and
treated with different concentrations of the CLE. After in-
cubation for a week, it was observed that at a dose of 25 μg
GAE of CLE, no colonies were found in either MDA-MB-
231 (Figure 2A) or MCF-7 cells (Figure 2B). In line with
our observations on cell viability (MTT assay), MDA-MB-
231 cells appeared to be more sensitive than MCF-7 cells.
This is supported by our findings where a lesser concentra-
tion of CLE was needed to inhibit the formation of colonies
in MDA-MB-231 cells in comparison to MCF-7 cells.
M. koenigii leaf extract induces growth arrest and
apoptosis in breast cancer cells
Cell cycle experiments were done to determine whether
CLE treatment arrested growth in MDA-MB-231 and
MCF-7 cells. In both the breast carcinoma cell lines CLE
treatment showed a dose-dependent arrest in the S
phase of the cell cycle resulting in complete inhibition of
cell proliferation (Figures 3 and 4; Tables 1 and 2). That
inhibition of cell proliferation denoted by G2-M phase
was observed at 12.5 μg GAE in MDA-MB-231 cells,
whereas, in MCF-7 cells it was seen at 37.5 μg GAE,
corroborates the greater sensitivity of MDA-MB-231
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ingly, CLE had no effect on cell cycle in the normal WI-38
cell line at any of the concentrations tested (Figure 5 and
Table 3), indicating that CLE could arrest growth only in
cancer but not normal cells.
Further, Annexin-V binding experiments were conducted
in both cell lines to determine the probable mechanism of
cell death. That 6μg CLE resulted in 45% of live MDA-MB-
231 cells whereas, a dose of 12.5 μg CLE was required for a
similar effect in MCF-7 cells not only confirms the greater
sensitivity of MDA-MB-231 than MCF-7 cells but also sug-
gests apoptosis to be the probable mechanism of cell death.
This is confirmed by our finding that CLE demonstrated a
dose dependent increase in the % of apoptotic cells in both
MDA-MB-231 and MCF-7 cells. 50% of cells were apop-
totic with 6 μg CLE in MDA-MB-231 cell line and it
increased to 66% at a dose of 37.5 μg CLE (Figure 6). A
similar dose dependent increase in the % apoptotic cells
was seen in MCF-7 cells (Figure 7).
M. koenigii leaf extract inhibits 20S purified proteasome
activity
We then tested whether or not CLE inhibited the activity
of the purified 20S rabbit proteasome in a cell-free system.
Indeed CLE decreased the chymotrypsin-like activity of
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Figure 10 Inhibition of the enzymatic activities of the 26S proteasom
normal cell line. Intact MCF-7 or WI-38 cells were treated for 24 h with o
fluorogenic substrate for either Ch-L or T-L or Cp-L activities respectively. T
multimode reader with excitation (380 nm) and emission (460 nm). Each a
100%). Panel D depicts results from WI-38 cells. Panels A & D represents50% decrease (IC50) in activity was seen at a concentration
of CLE equivalent to 3 ug of Gallic Acid (GAE)/μl of the
extract (Figure 8).
M. koenigii leaf extract inhibits cellular 26S proteasome
activity in intact cells
Whether the CLE also inhibited the activity of the 26S
proteasome in living cancer cells was assessed next in
both MCF-7 and MDA-MB-231 cells. Similar to its
effects on the purified 20S rabbit proteasome, CLE
showed a significant (p<0.05), dose-dependent decrease
in the chymotrypsin-like, trypsin-like and caspase-like
activities of the 26S proteasome in intact cancer cells
(Figures 9 and 10).
On the other hand, CLE did not inhibit the
chymotrypsin-like activity of the 26S proteasome at
any of the concentrations tested in the normal WI-
38 cells (Figure 10D) indicating the specificity of the
effect to cancer cells.
M. koenigii leaf extract inhibits cellular 26S proteasome
activity in cell extracts
Further to confirm that the CLE inhibits the 26S prote-
asome, cell extracts enriched in 26S proteasomes were
prepared from both MCF-7 and MDA-MB-231 cells.
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A
Figure 11 Concentration-dependent inhibition of the enzymatic activities of the 26S proteasome by the CLE or MG-132 in MDA-MB-
231 cell extracts. Cell extracts (=50 μg protein) were incubated with 50 μM of the fluorogenic substrates specific for Ch-L, T-L and Cp-L activities
in the presence of various concentrations of the CLE for 2 h at 37°C. Each activity was expressed as the percentage of the control (defined as
100%). Panel A, B & C depicts Ch-L, T-L and Cp-L activities respectively, whereas panel D depict Ch-L activity with the synthetic proteasome
inhibitor MG-132.
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It was interesting that CLE inhibited the chymotrypsin-
like, trypsin-like and caspase-like activities of the 26S pro-
teasome in cell extracts in a dose-dependent manner in
both MDA-MB-231 [IC50 of 22.5 μg CLE] and MCF-7
cells [IC50 of 30 μg CLE] (Figures 11 and 12). As a positive
control MG-132, a proteasome inhibitor was also tested. It
was observed that MG-132 decreased the chymotrypsin-
like activity of the 26S proteasome in a dose-dependent
manner in cell extracts prepared from both MDA-MB-
231 and MCF-7 cells with an IC50 of >50 nM and 25 nM
in the two cell lines respectively (Figures 11D & 12C).
Discussion
Search for new anti-cancer drugs from natural sources is
one of the most important approaches for cancer pre-
vention and treatment. In recent years, more emphasis
is laid on Complementary and Alternative [CAM] forms
of medicine for the treatment of various cancers, among
which herbal medicine is now being explored for cancer
therapy [36]. Dietary constituents have chemopreventive
and chemotherapeutic potential, in addition to amelior-
ating the side effects associated with conventional
chemotherapy. In this context, a recent approach in can-
cer therapy advocates the inhibition of the proteolytic
activity of 26S proteasome, the multi-enzymatic protease
complex in cells. Unlike normal cells, cancer cells haveincreased proteasomal activity which is essential for their
survival and uninhibited proliferation [37-39]. Inhibition
of the proteasome results in apoptosis and cancer cell
death [40]. Importantly, inhibitors of the 20S proteolytic
unit of the proteasome have been shown to induce
apoptosis and cell cycle arrest only in neoplastic cells
but not in normal cells [39-41]. Therefore, the prote-
asome has emerged as an attractive molecular target for
cancer therapy [42]. A number of synthetic proteasome
inhibitors have been described and most of them inter-
fere with the proteolytic activity of the β subunits of the
20S proteasome. These inhibitors which bind the active
site either reversibly or irreversibly include peptide alde-
hydes such as MG-132, non-peptide inhibitors such as
lactacystin and epoxomycin and peptide boronates such
as bortezomib [43].
Bortezomib/Velcade/PS-341 is the first-in-line and
the only dipeptide boronate proteasome inhibitor to
be approved by the FDA in 2003 for the treatment of
patients with refractory multiple myeloma. Bortezomib
is now being tested in a variety of hematological and
solid tumors including non-Hodgkin’s lymphoma, pros-
tate, breast and non-small-cell-lung cancer [44,45]. In
recent years, synthetic polyphenols such as apigenin,
epigallocatechin gallate [EGCG], quercitin and myrcetin
have been reported to act as proteasome inhibitors and
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Figure 12 Concentration-dependent inhibition of the enzymatic
activities of the 26S proteasome by the CLE or MG-132 in
MCF-7 cell extracts. Cell extracts (=50 μg protein) were incubated
with 50 μM of the fluorogenic substrates specific for Ch-L, T-L and Cp-L
activities in the presence of various concentrations of the CLE for 2 h at
37°C. Each activity was expressed as the percentage of the control
(defined as 100%). Panel A & B depicts Ch-L and T-L activities
respectively, whereas panel C depicts Ch-L activity with MG-132.
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ment options and is a major challenge faced in current
cancer research. Interestingly, it has been shown that lac-
tacystin and bortezomib enhance sensitivity of cancer cells
that are resistant to routine chemotherapy [46,47]. Never-
theless, synthetic proteasome inhibitors are associated
with some toxicity. Therefore, proteasome inhibitors from
natural food sources with minimal or no toxicity can be
potential anticancer agents.
In the present study, we report the anticancer potential
of M. koenigii leaf extracts in two human breast carcin-
oma cell lines. In recent years, dietary polyphenols have
attracted lot of attention owing to their anti-tumor activ-
ities [48,49]. One such activity is the inhibition of the
proteasome in cancer cells leading to cell death. Recent
work from our laboratory [21] has demonstrated that M.
koenigii leaf extract is a rich source of polyphenols. In
this study, we found that a hydro-methanolic extract of
curry leaves is rich in polyphenol content. Extracts of M.
koenigii leaves have been reported to possess various bio-
logical activities such as anti-diabetic, anti-oxidative and
anti-inflammatory [8-10]. Recently, carbazole alkaloids
from M. koenigii have shown anti-cancer activity in
leukemia cells [18-20]. However, the underlying mechan-
ism(s) are not reported yet. In the present work, we dem-
onstrate for the first time that the hydro-methanolic
extract of curry leaf has proteasome-inhibitory potential
and induces cell death in human breast cancer cells.
We found that the methanolic extract of curry leaves
significantly decreased cell viability and proliferation of
both MCF-7 and MDA-MB-231 breast cancer cells in a
dose-dependent manner. This was further supported by
the significant reduction in the number of colonies in
CLE treated cells compared to vehicle treated cells. Our
cell viability and colony formation data shows that CLE
altered the growth kinetics of both MCF-7 and MDA-
MB-231 cells. Therefore, curry leaves appear to be a
promising drug candidate for restricting the growth of
breast cancer cells.
In order to assess the stage at which the cell growth
was arrested by CLE, we performed cell cycle experi-
ments and observed that there was a clear arrest of cells
in the synthetic or S phase. In contrast to its effect on
the breast carcinoma cell lines, CLE interestingly, had
no effect on the different phases of the cell cycle in the
normal fibroblast cell line. Anti-cancer drugs can result
either in programmed cell death/apoptosis or necrosis.
In order to identify the probable cell death pathway
involved, we used Annexin V binding to test if the cell
death occurred through apoptosis or necrosis. Indeed it
was found that in both the breast cancer cell lines CLE
induced apoptotic cell death.
We tested next, whether the anti-cancerous effect of the
CLE was due its potential of inhibiting the proteolytic
Noolu et al. BMC Complementary and Alternative Medicine 2013, 13:7 Page 16 of 17
http://www.biomedcentral.com/1472-6882/13/7activity of the protein degrading machine present in
eukaryotic cells – the 26S proteasome, which is now con-
sidered to be a novel approach for cancer therapy. We
observed that CLE inhibited the purified 20S proteasome
enzyme. Furthermore, it significantly inhibited all the
three enzymatic activities associated with the 26S prote-
asome in living cells in a dose-dependent manner. To fur-
ther confirm the findings in live cells, cell extracts were
prepared from both breast cancer cells and tested for the
potential of the CLE in inhibiting the cellular proteasome.
Similar to our findings in intact cells we found that CLE
inhibited the 26S proteasome in cell extracts also in a
dose-dependent manner. To test whether or not the in-
hibitory effect of the CLE on the proteasome activity was
specific to cancer cells, we tested its effects in WI-38, a
normal lung fibroblast cell line. Interestingly, CLE had no
effect on the chymotrypsin–like activity of the 26S
proteasome in live WI-38 cells. Hence, data from our
proteasome-inhibition experiments suggests that the
CLE could inhibit the cellular proteasome leading to
cell death in cancer cells but not normal cells. Our data
is in accordance with earlier reports that proteasome
inhibitors selectively inhibited proteasome activity only
in neoplastic cells [39,50,51].
Conclusion
Our results indicate that the hydro-methanolic extract
of curry leaves is a good source of active compound(s)
that can potentially inhibit the 26S proteasome specific-
ally in cancer cells. The inhibition of the proteasome in
cancer cells appears to be one of the important biological
activities in M. koenigii leaves that can be exploited for
cancer treatment. Hence, isolation and characterization of
active component(s) from methanolic extracts of curry




(GAE): Gallic Acid Equivalents; (CLE): Curry leaf extract; (AMC): 7-amino-4-
methylcoumarin; (DMSO): Dimethyl sulphoxide; (EGCG): Epigallocatechin
gallate; (DTT): Dithiothretol; (FITC): Fluorescein isothiocyanate;
(PBS): Phosphate buffered saline.
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